European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis
WERNER R. N.; NIKKELS, Arjen; MARINOVIC B.et al.
2017 • In Journal of the European Academy of Dermatology and Venereology, 31, p. 9-19
[en] Herpes zoster (HZ, shingles) is a frequent medical condition which may severely impact the quality of life of affected patients. Different therapeutic approaches to treat acute HZ are available. The aim of this European project was the elaboration of a consensus-based guideline on the management of patients who present with HZ, considering different patient populations and different localizations. This interdisciplinary guideline aims at an improvement of the outcomes
of the acute HZ management concerning disease duration, acute pain and quality of life of the affected patients and at a reduction of the incidence of postherpetic neuralgia and other complications. The guideline development followed a structured and predefined process, considering the quality criteria for guidelines development as suggested by the AGREE II instrument. The steering group was responsible for the planning and the organization of the guideline development process (Division of Evidence based Medicine, dEBM). The expert panel was nominated by virtue of clinical expertise and/or scientific experience and included experts from the fields of dermatology, virology/infectiology, ophthalmology, otolaryngology, neurology and anaesthesiology. Recommendations for clinical practice were formally consented during the consensus conference, explicitly considering different relevant aspects. The guideline was
approved by the commissioning societies after an extensive internal and external review process. In this first part of the guideline, diagnostic means have been evaluated. The expert panel formally consented recommendations for the management of patients with (suspected) HZ, referring to the assessment of HZ patients, considering various specific clinical situations. Users of the guideline must carefully check whether the recommendations are appropriate for the context of
intended application. In the setting of an international guideline, it is generally important to consider different national approaches and legal circumstances with regard to the regulatory approval, availability and reimbursement of diagnostic and therapeutic interventions.
Disciplines :
Dermatology
Author, co-author :
WERNER R. N.
NIKKELS, Arjen ; Centre Hospitalier Universitaire de Liège - CHU > Service de dermatologie
European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis
Publication date :
January 2017
Journal title :
Journal of the European Academy of Dermatology and Venereology
Cohen JI. Herpes zoster. N Engl J Med 2013; 369: 255–263.
Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol 1987; 7: 174–178.
Jones M, Dry IR, Frampton D, et al. RNA-seq analysis of host and viral gene expression highlights interaction between varicella zoster virus and keratinocyte differentiation. PLoS Pathog 2014; 10: e1003896.
Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20: 748–753.
Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605–1609.
Pinchinat S, Cebrian-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013; 13: 170.
Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology 2013; 81: 928–930.
Gil-Prieto R, Walter S, Gonzalez-Escalada A, Garcia-Garcia L, Marin-Garcia P, Gil-de-Miguel A. Different vaccination strategies in Spain and its impact on severe varicella and zoster. Vaccine 2014; 32: 277–283.
Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995; 45: S52–S53.
Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss 2012; 20: 441–451.
Moanna A, Rimland D. Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era. Clin Infect Dis 2013; 57: 122–125.
Bricout H, Haugh M, Olatunde O, Prieto RG. Herpes zoster-associated mortality in Europe: a systematic review. BMC Public Health 2015; 15: 466.
Chen N, Li Q, Zhang Y, Zhou M, Zhou D, He L. Vaccination for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2011; 3: CD007795.
AGREE Next Steps Consortium. The AGREE II Instrument [WWW document] 2009. URL http://www.agreetrust.org (Last accessed on 03 June 2016).
Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719–725.
Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9–20.
Meister W, Neiss A, Gross G, et al. Demography, symptomatology, and course of disease in ambulatory zoster patients. A physician-based survey in Germany. Intervirology 1998; 41: 272–277.
Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61: 310–316.
Pedrosa A, Cruz MJ, Mota A, Baudrier T, Azevedo F. Herpes zoster multiplex and bilateral in an immunocompetent child. Pediatr Infect Dis J 2015; 34: 225–226.
Johnson RW, Alvarez-Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines 2015; 3: 109–120.
Volpi A, Gross G, Hercogova J, Johnson RW. Current management of herpes zoster: the European view. Am J Clin Dermatol 2005; 6: 317–325.
Gross G, Schofer H, Wassilew S, et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003; 26: 277–289; discussion 91-3.
Zerngast WW, Paauw DS, O'Connor KM. Varicella zoster with extended prodrome: a case series. Am J Med 2013; 126: 359–361.
Kalman CM, Laskin OL. Herpes zoster and zosteriform herpes simplex virus infections in immunocompetent adults. Am J Med 1986; 81: 775–778.
Rubben A, Baron JM, Grussendorf-Conen EI. Routine detection of herpes simplex virus and varicella zoster virus by polymerase chain reaction reveals that initial herpes zoster is frequently misdiagnosed as herpes simplex. Br J Dermatol 1997; 137: 259–261.
Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123: 89–96.
Yamamoto S, Shimomura Y, Kinoshita S, Tano Y. Differentiating zosteriform herpes simplex from ophthalmic zoster. Arch Ophthalmol 1994; 112: 1515–1516.
El Hayderi L, Libon F, Nikkels-Tassoudji N, Ruebben A, Dezfoulian B, Nikkels AF. Zosteriform dermatoses-A review. Global Dermatol 2015; 2: 163–173.
Sauerbrei A, Eichhorn U, Schacke M, Wutzler P. Laboratory diagnosis of herpes zoster. J Clin Virol 1999; 14: 31–36.
Wilson DA, Yen-Lieberman B, Schindler S, Asamoto K, Schold JD, Procop GW. Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review. J Clin Microbiol 2012; 50: 4120–4122.
Levin MJ. Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections. J Clin Virol 2014; 61: 487–495.
Nagel MA, Choe A, Cohrs RJ, et al. Persistence of varicella zoster virus DNA in saliva after herpes zoster. J Infect Dis 2011; 204: 820–824.
Quinlivan ML, Ayres KL, Kelly PJ, et al. Persistence of varicella-zoster virus viraemia in patients with herpes zoster. J Clin Virol 2011; 50: 130–135.
Aberle SW, Aberle JH, Steininger C, Puchhammer-Stockl E. Quantitative real time PCR detection of Varicella-zoster virus DNA in cerebrospinal fluid in patients with neurological disease. Med Microbiol Immunol 2005; 194: 7–12.
Knox CM, Chandler D, Short GA, Margolis TP. Polymerase chain reaction-based assays of vitreous samples for the diagnosis of viral retinitis – Use in diagnostic dilemmas. Ophthalmology 1998; 105: 37–44.
Persson A, Bergstrom T, Lindh M, Namvar L, Studahl M. Varicella-zoster virus CNS disease-viral load, clinical manifestations and sequels. J Clin Virol 2009; 46: 249–253.
Rottenstreich A, Oz ZK, Oren I. Association between viral load of varicella zoster virus in cerebrospinal fluid and the clinical course of central nervous system infection. Diagn Microbiol Infect Dis 2014; 79: 174–177.
Engelmann I, Petzold DR, Kosinska A, Hepkema BG, Schulz TF, Heim A. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol 2008; 80: 467–477.
Tan TY, Zou H, Ong DCT, et al. Development and clinical validation of a multiplex real-time PCR assay for herpes simplex and varicella zoster virus. Diagn Mol Pathol 2013; 22: 245–248.
van Velzen M, Ouwendijk WJ, Selke S, et al. Longitudinal study on oral shedding of herpes simplex virus 1 and varicella-zoster virus in individuals infected with HIV. J Med Virol 2013; 85: 1669–1677.
Coffin SE, Hodinka RL. Utility of direct immunofluorescence and virus culture for detection of varicella-zoster virus in skin-lesions. J Clin Microbiol 1995; 33: 2792–2795.
Dahl H, Marcoccia J, Linde A. Antigen detection: the method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus-infected patients. J Clin Microbiol 1997; 35: 347–349.
Nikkels AF, Delvenne P, Debrus S, et al. Distribution of varicella-zoster virus gpI and gpII and corresponding genome sequences in the skin. J Med Virol 1995; 46: 91–96.
Folkers E, Vreeswijk J, Oranje AP, Duivenvoorden JN. Rapid diagnosis in varicella and herpes-zoster – re-evaluation of direct smear (Tzanck Test) and electron-microscopy including colloidal gold immuno-electron microscopy in comparison with virus isolation. Br J Dermatol 1989; 121: 287–296.
Nahass GT, Goldstein BA, Zhu WY, Serfling U, Penneys NS, Leonardi CL. Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection. JAMA 1992; 268: 2541–2544.
Schirm J, Meulenberg JJM, Pastoor GW, Vader PCV, Schroder FP. Rapid detection of varicella-zoster virus in clinical specimens using monoclonal-antibodies on shell vials and smears. J Med Virol 1989; 28: 1–6.
Pleyer U, Metzner S, Hofmann J. Diagnostics and differential diagnosis of acute retinal necrosis. Ophthalmologe 2009; 106: 1074–1082.
Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clin Proc 2013; 88: 562–570.
Johnson JL, Amzat R, Martin N. Herpes zoster ophthalmicus. Prim Care 2015; 42: 285–303.
Kido S, Sugita S, Horie S, et al. Association of varicella zoster virus load in the aqueous humor with clinical manifestations of anterior uveitis in herpes zoster ophthalmicus and zoster sine herpete. Br J Ophthalmol 2008; 92: 505–508.
Robert PY, Liekfeld A, Metzner S, et al. Specific antibody production in herpes keratitis: intraocular inflammation and corneal neovascularisation as predicting factors. Graefes Arch Clin Exp Ophthalmol 2006; 244: 210–215.
Dickins JR, Smith JT, Graham SS. Herpes zoster oticus: treatment with intravenous acyclovir. Laryngoscope 1988; 98: 776–779.
Shin DH, Kim BR, Shin JE, Kim CH. Clinical manifestations in patients with herpes zoster oticus. Eur Arch Otorhinolaryngol 2015; 273: 1739–1743.
Hadar T, Tovi F, Sarov B, Sidi J, Sarov I. Detection of specific iga antibodies to varicella zoster virus in serum of patients with Ramsay Hunt syndrome. Ann Otol Rhinol Laryngol 1990; 99: 461–465.
Ikeda M, Hiroshige K, Abiko Y, Onoda K. Impaired specific cellular immunity to the varicella-zoster virus in patients with herpes zoster oticus. J Laryngol Otol 1996; 110: 918–921.
Furuta Y, Fukuda S, Suzuki S, Takasu T, Inuyama Y, Nagashima K. Detection of varicella-zoster virus DNA in patients with acute peripheral facial palsy by the polymerase chain reaction, and its use for early diagnosis of zoster sine herpete. J Med Virol 1997; 52: 316–319.
Wauters O, Lebas E, Nikkels AF. Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections. J Am Acad Dermatol 2012; 66: e217–e227.
Muraki R, Iwasaki T, Sata T, Sato Y, Kurata T. Hair follicle involvement in herpes zoster: pathway of viral spread from ganglia to skin. Virchows Arch 1996; 428: 275–280.
Nikkels AF, Pierard GE. Are granulomatous reactions in old zoster lesions due to an immune response to varicella zoster virus envelope glucoproteins? Clin Exp Dermatol 1998; 23: 237–238.
Chiang F, Panyaping T, Tedesqui G, Sossa D, Costa Leite C, Castillo M. Varicella zoster CNS vascular complications. A report of four cases and literature review. Neuroradiol J 2014;27:327–333.
Gilden D, Nagel M. Varicella zoster virus in temporal arteries of patients with giant cell arteritis. J Infect Dis 2015; 212(Suppl 1): S37–S39.
Gilden DH, Mahalingam R, Cohrs RJ, Kleinschmidt-DeMasters BK, Forghani B. The protean manifestations of varicella-zoster virus vasculopathy. J Neurovirol 2002; 8(Suppl 2): 75–79.
Grahn A, Studahl M. Varicella-zoster virus infections of the central nervous system – prognosis, diagnostics and treatment. J Infect 2015; 71: 281–293.
Nagel MA, Forghani B, Mahalingam R, et al. The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology 2007; 68: 1069–1073.
Guess HA, Broughton DD, Melton LJ 3rd, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics 1985; 76: 512–517.
Petursson G, Helgason S, Gudmundsson S, Sigurdsson JA. Herpes zoster in children and adolescents. Pediatr Infect Dis J 1998; 17: 905–908.
Nikkels AF, Nikkels-Tassoudji N, Pierard GE. Revisiting childhood herpes zoster. Pediatr Dermatol 2004; 21: 18–23.
Yawn BP, Wollan PC, Kurland MJ, Sauver JLS, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011; 86: 88–93.
Forbes HJ, Thomas SL, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 2016; 157: 30–54.
Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005-2009. J Infect 2015; 70: 178–186.
Ghaznawi N, Virdi A, Dayan A, et al. Herpes zoster ophthalmicus: comparison of disease in patients 60 years and older versus younger than 60 years. Ophthalmology 2011; 118: 2242–2250.
Meister W, Neiss A, Gross G, et al. A prognostic score for postherpetic neuralgia in ambulatory patients. Infection 1998; 26: 359–363.
Nikkels AF, Delvenne P, Sadzot-Delvaux C, et al. Distribution of varicella zoster virus and herpes simplex virus in disseminated fatal infections. J Clin Pathol 1996; 49: 243–248.
Volpi A. Severe complications of herpes zoster. Herpes 2007; 14(Suppl 2): 35–39.
Jemsek J, Greenberg SB, Taber L, Harvey D, Gershon A, Couch RB. Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine (Baltimore) 1983; 62: 81–97.
De La Blanchardiere A, Rozenberg F, Caumes E, et al. Neurological complications of varicella-zoster virus infection in adults with human immunodeficiency virus infection. Scand J Infect Dis 2000; 32: 263–269.
Hughes BA, Kimmel DW, Aksamit AJ. Herpes zoster-associated meningoencephalitis in patients with systemic cancer. Mayo Clin Proc 1993; 68: 652–655.
el Hayderi L, Bontems S, Nikkels-Tassoudji N, et al. Satellite lesions accompanying herpes zoster: a new prognostic sign for high-risk zoster. Br J Dermatol 2015; 172: 1530–1534.
Nagasako EM, Johnson RW, Griffin DR, Dworkin RH. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. J Am Acad Dermatol 2002; 46: 834–839.
Haanpaa M, Dastidar P, Weinberg A, et al. CSF and MRI findings in patients with acute herpes zoster. Neurology 1998; 51: 1405–1411.
Ludlow M, Kortekaas J, Herden C, et al. Neurotropic virus infections as the cause of immediate and delayed neuropathology. Acta Neuropathol 2016; 131: 159–184.
Breuer J, Pacou M, Gauthier A, Brown MM. Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Neurology 2014; 82: 206–212.
Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis 2014; 58: 1497–1503.
Minassian C, Thomas SL, Smeeth L, Douglas I, Brauer R, Langan SM. Acute cardiovascular events after herpes zoster: a self-controlled case series analysis in vaccinated and unvaccinated older residents of the United States. PLoS Med 2015; 12: e1001919.
Naveen KN, Tophakane RS, Hanumanthayya K, Pv B, Pai VV. A study of HIV seropositivity with various clinical manifestation of herpes zoster among patients from Karnataka, India. Dermatol Online J 2011; 17: 3.
Sharvadze L, Tsertsvadze T, Gochitashvili N, Stvilia K, Dolmazashvili E. Hiv prevalence among high risk behavior group persons with herpes zoster infection. Georgian Med News 2006; 132: 60–64.
Sullivan AK, Raben D, Reekie J, et al. Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS ONE 2013; 8: e52845.
Wang YP, Liu CJ, Hu YW, Chen TJ, Lin YT, Fung CP. Risk of cancer among patients with herpes zoster infection: a population-based study. Can Med Assoc J 2012; 184: E804–E809.
Cotton SJ, Belcher J, Rose P, Jagadeesan SK, Neal RD. The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study. Br J Cancer 2013; 108: 721–726.
Safrin S, Berger TG, Gilson I, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991; 115: 19–21.
Saint-Léger E, Caumes E, Breton G, et al. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 33: 2061–2067.
Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2. J Antimicrob Chemother 2016; 71: 6–16.
Brunnemann AK, Bohn-Wippert K, Zell R, et al. Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate. Antimicrob Agents Chemother 2015; 59: 2726–2734.
Sauerbrei A, Taut J, Zell R, Wutzler P. Resistance testing of clinical varicella-zoster virus strains. Antiviral Res 2011; 90: 242–247.
Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH Jr. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994; 170: 68–75.
Bhalla P, Forrest GN, Gershon M, et al. Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect Dis 2015; 60: 1068–1074.
Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep 2016; 2016: 1–3.
Depledge DP, Kundu S, Jensen NJ, et al. Deep sequencing of viral genomes provides insight into the evolution and pathogenesis of varicella zoster virus and its vaccine in humans. Mol Biol Evol 2014; 31: 397–409.
